<DOC>
	<DOCNO>NCT00184093</DOCNO>
	<brief_summary>The purpose study first establish ideal dose gemcitabine , chemotherapy agent , give combination radiation . In addition , investigator want determine side effect effectiveness combination . The investigator also study several marker try identify marker test predict patient benefit treatment .</brief_summary>
	<brief_title>Study Gemcitabine Concurrent Radiation Followed Adjuvant Hysterectomy Bulky Stage Ib IIa Cervical Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patients histologically confirm bulky stage Ib stage IIa cervical cancer . Bulky stage Ib disease define tumor mass great 4 cm diameter . Cervical lesion measurable physical examination . No prior therapy invasive cervical cancer . GOG performance status 02 Signed informed consent Patients must adequate : Bone marrow function : absolute granulocyte count &gt; = 1500 , platelet count &gt; 100,000 . Renal function : creatinine &lt; = 1.8 mg/dl Hepatic function : bilirubin &lt; = 1.5 x normal , SGOT alkaline phosphatase &lt; = 3 x normal Patients history prior malignancy , except adequately treat basal cell squamous cell carcinoma skin , cancer patient disease free least five year . Pregnant lactating woman . Women reproductive age may participate unless agree use effective method birth control . Patients uncontrolled infection . Patients HIV positive Patients psychiatric social condition would interfere consent followup . Patients severe concurrent disease , , judgment investigator , would make patient inappropriate entry study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Cervical Carcinoma</keyword>
</DOC>